{"id":685791,"date":"2024-01-25T15:36:01","date_gmt":"2024-01-25T15:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=685791"},"modified":"2024-01-25T15:36:01","modified_gmt":"2024-01-25T15:36:01","slug":"mercks-prevymis-letermovir-market-size-expected-to-increase-many-folds-by-2030-report-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/mercks-prevymis-letermovir-market-size-expected-to-increase-many-folds-by-2030-report-delveinsight_685791.html","title":{"rendered":"Merck\u2019s Prevymis (letermovir) market size expected to increase many folds by 2030, report DelveInsight"},"content":{"rendered":"
\n
\"Merck’s<\/a><\/div>\n
\n
Prevymis (letermovir) market<\/div>\n<\/div>\n<\/div>\n

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Merck’s Prevymis (letermovir) providing insights into the drug market landscape and market forecast of Prevymis (letermovir) upto 2030. The report, titled “Prevymis (letermovir) – Market Size, Forecast, and Drug Insight – 2030”<\/strong> is now available for review and analysis.<\/p>\n

Are you interested in finding out the projected market size of Prevymis (letermovir) in 2030? Click @ Prevymis (letermovir) market size<\/a><\/em><\/strong><\/p>\n

The Prevymis (letermovir) Market Report offers projected sales forecasts for Prevymis (letermovir) for indications until 2030, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.<\/p>\n

Prevymis (letermovir) Overview<\/strong><\/p>\n

Merck’s Prevymis (letermovir) is serving as a beacon of hope for the patients suffering from the Cytomegalovirus (CMV) infection.<\/p>\n

PREVYMIS is an antiviral agent that was initially approved by the FDA in 2017 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). PREVYMIS is administered once-daily as an oral tablet or as an injection for intravenous infusion.<\/p>\n

PREVYMIS is contraindicated in patients receiving pimozide or ergot alkaloids. Increased pimozide concentrations due to concomitant administration of PREVYMIS may lead to QT prolongation and torsades de pointes. Increased ergot alkaloids concentrations due to concomitant administration of PREVYMIS may lead to ergotism. PREVYMIS is contraindicated with pitavastatin and simvastatin when co-administered with cyclosporine. Significantly increased pitavastatin or simvastatin concentrations may lead to myopathy or rhabdomyolysis.<\/p>\n

The report extensively covers the details and developments related to Prevymis (letermovir), capturing important highlights on developmental pipeline, regulatory status and special designations of Prevymis (letermovir), route of administration, safety and efficacy details.<\/p>\n

Do you know your drug’s competitive positioning against Prevymis (letermovir)? Download Report : Prevymis (letermovir) market dynamics<\/a><\/em><\/strong><\/p>\n

Prevymis (letermovir) Market Assessment<\/strong><\/p>\n

This report provides a detailed market assessment of Prevymis (letermovir) for Cytomegalovirus (CMV) infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2030.<\/p>\n

Prevymis (letermovir) Clinical Assessment<\/strong><\/p>\n

The report provides the clinical trials information of Prevymis (letermovir) for Cytomegalovirus (CMV) infection covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related. <\/p>\n

Prevymis (letermovir) Competitive Landscape <\/strong><\/p>\n

The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Prevymis (letermovir).<\/p>\n

Prevymis (letermovir) Market Size in the US<\/strong><\/p>\n

A dedicated section of the report focuses on the expected market size of Prevymis (letermovir) for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.<\/p>\n

What is a Prevymis (letermovir) Prescribed for?<\/strong><\/p>\n

Merck’s Prevymis (letermovir) is Prescribed for Cytomegalovirus (CMV) infection.<\/p>\n

Key Highlights of Prevymis (letermovir): <\/strong><\/p>\n